FORA Capital’s Terns Pharmaceuticals TERN Stock Holding History

FORA Capital’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.43M	Sell	27,120 -6,608	-20%	-$271K	0.1%	196
2025 Q4	$1.36M	Buy	+33,728	New	+$779K	0.16%	166

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

FORA Capital's TERN Position: Q1 2026 in Review

FORA Capital reduced its Terns Pharmaceuticals (TERN) stake by 20% in Q1 2026, selling an estimated $271K and leaving 27,120 shares worth $1.43M. The position accounts for 0.1% of the portfolio, ranked #196.

FORA Capital first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

FORA Capital held 27,120 shares of Terns Pharmaceuticals worth $1.43M as of Q1 2026.
FORA Capital sold 6,608 Terns Pharmaceuticals shares in Q1 2026, an estimated $271K.
Terns Pharmaceuticals made up 0.1% of FORA Capital's portfolio in Q1 2026, its #196 holding.
FORA Capital first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.